Improving outcomes for aging and high-need populations KANSAS CITY, Mo., March 9, 2025 /PRNewswire/ — Trualta, the leading learning and support platform for caregivers, has released its latest impact report, Moments That Matter, analyzing three million minutes of caregiver activity on…
Category: Uncategorized
Strategic partnership strengthens regulatory compliance across HashKey Global’s international exchange network. SINGAPORE, March 9, 2025 /PRNewswire/ — HashKey Global, a leading licensed exchange, and VerifyVASP, a global Travel Rule solution provider, have announced a strategic…
Strategic partnership strengthens regulatory compliance across HashKey Global’s international exchange network. SINGAPORE, March 9, 2025 /PRNewswire/ — HashKey Global, a leading licensed exchange, and VerifyVASP, a global Travel Rule solution provider, have announced a strategic…
Strategic partnership strengthens regulatory compliance across HashKey Global’s international exchange network. SINGAPORE, March 9, 2025 /PRNewswire/ — HashKey Global, a leading licensed exchange, and VerifyVASP, a global Travel Rule solution provider, have announced a strategic…
PRINCETON, N.J., March 9, 2025 /PRNewswire/ — RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH)…
HONG KONG, March 9, 2025 /PRNewswire/ — On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology and Zhejiang University was awarded the Global Mobile Award (GLOMO…
TOKYO, March 9, 2025 /PRNewswire/ — Seven & i Holdings Co., Ltd. (“7&i,” “the Group,” or “the Company”) today sent the following letter to its shareholders to provide additional information related to the Special Committee’s ongoing engagement with Alimentation Couche-Tard (“ACT”) and…
SAN DIEGO, March 9, 2025 /PRNewswire/ — Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired AppLovin Corporation (NASDAQ: APP) securities between May 10, 2023 and February 25, 2025. AppLovin Corporation engages in…
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] The…
SAN DIEGO, March 9, 2025 /PRNewswire/ — Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired e.l.f. Beauty, Inc. (NYSE: ELF) securities between November 1, 2023 and November 19, 2024. e.l.f., together with its…